Despite remarkable success in treating obesity, glucagon‐like peptide‐1 receptor agonists (GLP1‐RAs) face challenges including limited efficacy in some individuals, gastrointestinal side effects, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results